Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 111 peer-reviewed journal articles Updated
Cardiology · Anthracycline-Induced Cardiomyopathy

Anthracycline-Induced Cardiomyopathy: A Patient Guide

At a Glance

Anthracycline-induced cardiomyopathy can appear during treatment or years later, often before symptoms. Regular echocardiograms, strain measurements, and blood biomarkers help detect heart stress early, when medication and treatment adjustments may support recovery.

Anthracycline-induced cardiomyopathy is a condition where specific chemotherapy drugs—such as doxorubicin, epirubicin, and daunorubicin—affect the health and function of the heart muscle. Unlike many common heart issues that are caused by “plumbing” problems like blocked arteries, this condition is a “muscle” or “pump” problem [1]. The medicine travels through the bloodstream and interacts directly with the heart’s individual muscle cells, causing DNA stress and disrupting the energy factories (mitochondria) that keep the heart beating [2][3].

If you have already been diagnosed with an anthracycline-related heart change, your immediate next step is to coordinate with your oncology and cardiology teams to understand your specific results (such as your LVEF or strain values), confirm your medication plan, and establish clear guidelines on what symptoms to report urgently.

The way this condition behaves is often gradual and cumulative, meaning the risk increases with the total amount of medicine you receive over your lifetime [4]. While some people experience heart stress during or shortly after treatment, others may not show signs for years or even decades [5][6]. Because early injury is almost always asymptomatic—meaning you cannot feel it happening—routine, risk-adapted heart monitoring is a vital part of your cancer care [7]. Doctors use advanced imaging like echocardiograms and blood tests for biomarkers (proteins that signal heart stress) to detect subtle changes long before they cause physical symptoms [8][9].

If heart stress is detected, it does not necessarily mean your cancer treatment must stop. In many cases, it is a signal for your multidisciplinary medical team to carefully weigh the cancer benefit against the cardiac risk. They may add protective heart medications or adjust your treatment plan to help support the heart muscle while you continue therapy [10][11]. When heart changes are caught early and treated promptly, some patients experience meaningful improvement in their heart function, though recovery is variable and depends on your individual situation [12][13].

In the long term, being a cancer survivor also means being a “heart advocate.” Protecting your heart reserve involves more than just monitoring for late-onset chemotherapy effects; it requires dedicated management of your overall health [14]. Working with your doctors to control your blood pressure, manage your cholesterol and blood sugar, and follow an individualized physical activity plan can significantly reduce your overall cardiovascular risk [15][16]. Your medical team is there to partner with you, using every tool available to support your heart health alongside your cancer recovery [17].

In this guide

7 chapters

01

Understanding Anthracycline Cardiotoxicity

Learn how anthracycline cardiotoxicity affects the heart, when it can appear, who is at risk, and how echocardiograms, GLS, and biomarkers guide monitoring.

02

Symptoms and Warning Signs

Learn the warning signs of anthracycline-related cardiomyopathy, including breathlessness, swelling, weight gain, palpitations, and when to seek emergency care.

03

How Anthracyclines Affect Your Heart Cells

Learn how anthracyclines injure heart cells through TOP2B, mitochondrial dysfunction, oxidative stress, iron damage, and cumulative effects on heart function.

04

Calculating and Managing Your Heart Risk

Learn how anthracycline cardiomyopathy risk is assessed with HFA-ICOS scoring, dose history, heart conditions, monitoring, and preventive treatment options.

05

Monitoring and Surveillance: Tracking Your Heart Health

Learn how heart monitoring for anthracycline cardiomyopathy uses echocardiograms, LVEF, GLS, troponin, and BNP to detect changes before symptoms appear.

06

Protecting and Treating Your Heart During Therapy

Learn how anthracycline cardiomyopathy is prevented and treated, including dexrazoxane, heart medicines, monitoring, and safer chemotherapy decisions.

07

Your Heart Health After Cancer: Long-Term Care

Learn about long-term heart care after anthracycline chemotherapy, including late risks, echocardiograms, recovery, and ways to protect your heart long term.

Common questions in this guide

What is anthracycline-induced cardiomyopathy?
It is a change in the heart muscle caused by anthracycline chemotherapy such as doxorubicin, epirubicin, or daunorubicin. These drugs can injure heart cells and reduce the heart’s pumping ability, sometimes during treatment and sometimes years later.
Does the total anthracycline dose affect my heart risk?
Yes. Risk generally rises as the total anthracycline dose received over a lifetime increases. Health factors such as blood pressure, cholesterol, and blood sugar also affect overall cardiovascular risk, so ask your oncology and cardiology teams how your personal history affects monitoring.
How can heart damage be detected before I notice symptoms?
Routine echocardiograms can measure the heart’s pumping function and strain, while blood tests for cardiac biomarkers can show heart stress or injury. These tests may identify changes before you notice shortness of breath or reduced exercise tolerance.
Does a change in heart tests mean my cancer treatment must stop?
Not necessarily. A change is a signal for oncology and cardiology teams to weigh the benefits of cancer treatment against cardiac risk; they may add heart-protective medicines or adjust the treatment plan. The decision depends on your individual test results and circumstances.
Can heart function improve after anthracycline cardiomyopathy is found?
Some patients have meaningful improvement when heart changes are detected and treated early, but recovery varies from person to person. Your clinicians can use your test results, symptoms, and treatment history to discuss recovery and follow-up.
How can I protect my heart after anthracycline chemotherapy?
Long-term follow-up may include heart monitoring even years after chemotherapy. Managing blood pressure, cholesterol, and blood sugar and following an individualized physical activity plan can help lower overall cardiovascular risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the planned total lifetime dose of anthracycline for my treatment, and does that put me in a higher risk category?
  2. 2.What are my baseline heart scan (LVEF and GLS) and blood test results, and how often will we repeat them?
  3. 3.If we see a change in my heart tests, what specific medications or treatment changes would we consider?
  4. 4.How will my heart health be monitored after I finish my chemotherapy, especially five or ten years from now?
  5. 5.Are there any specific lifestyle changes I should make right now to help protect my heart muscle during this treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Molecular mechanisms of anthracycline cardiovascular toxicity.

    Narezkina A, Narayan HK, Zemljic-Harpf AE

    Clinical science (London, England : 1979) 2021; (135(10)):1311-1332 doi:10.1042/CS20200301.

    PMID: 34047339
  2. 2

    Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.

    Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, et al.

    Circulation. Heart failure 2021; (14(11)):e008209 doi:10.1161/CIRCHEARTFAILURE.120.008209.

    PMID: 34551586
  3. 3

    Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.

    Wallace KB, Sardão VA, Oliveira PJ

    Circulation research 2020; (126(7)):926-941 doi:10.1161/CIRCRESAHA.119.314681.

    PMID: 32213135
  4. 4

    Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

    Henriksen PA

    Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

    PMID: 29217634
  5. 5

    Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity.

    Meshrkey F, Ibrahim SY, Bagchi RA, Richardson WJ

    Cells 2025; (14(18)) doi:10.3390/cells14181471.

    PMID: 41002436
  6. 6

    Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.

    Tantawy M, Pamittan FG, Singh S, Gong Y

    Clinical and translational science 2021; (14(1)):36-46 doi:10.1111/cts.12857.

    PMID: 32770710
  7. 7

    Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

    Armenian SH, Hudson MM, Mulder RL, et al.

    The Lancet. Oncology 2015; (16(3)):e123-36.

    PMID: 25752563
  8. 8

    Global Longitudinal Strain in Cardio-Oncology: A Review.

    Sławiński G, Hawryszko M, Liżewska-Springer A, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030986.

    PMID: 36765941
  9. 9

    Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

    Pudil R, Mueller C, Čelutkienė J, et al.

    European journal of heart failure 2020; (22(11)):1966-1983 doi:10.1002/ejhf.2017.

    PMID: 33006257
  10. 10

    Role of Myocardial Strain Imaging in Cancer Therapy-Related Cardiac Dysfunction.

    Chaganti BT, Negishi K, Okajima K

    Current cardiology reports 2022; (24(6)):739-748 doi:10.1007/s11886-022-01692-7.

    PMID: 35522421
  11. 11

    Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.

    Marwick TH, Dewar E, Nolan M, et al.

    European heart journal 2024; (45(41)):4414-4424 doi:10.1093/eurheartj/ehae574.

    PMID: 39217601
  12. 12

    Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

    Cardinale D, Colombo A, Bacchiani G, et al.

    Circulation 2015; (131(22)):1981-8 doi:10.1161/CIRCULATIONAHA.114.013777.

    PMID: 25948538
  13. 13

    Cardiotoxicity of Anthracyclines.

    Cardinale D, Iacopo F, Cipolla CM

    Frontiers in cardiovascular medicine 2020; (7()):26 doi:10.3389/fcvm.2020.00026.

    PMID: 32258060
  14. 14

    Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology.

    Rakisheva A, Farmakis D, Attanasio A, et al.

    European journal of heart failure 2025; (27(11)):2084-2099 doi:10.1002/ejhf.3753.

    PMID: 40679941
  15. 15

    Risk Factors for Anthracycline-Induced Cardiotoxicity.

    Qiu S, Zhou T, Qiu B, et al.

    Frontiers in cardiovascular medicine 2021; (8()):736854 doi:10.3389/fcvm.2021.736854.

    PMID: 34660739
  16. 16

    Effectiveness of exercise-based interventions in preventing cancer therapy-related cardiac dysfunction in patients with breast cancer: A systematic review and network meta-analysis.

    Zhang D, Xiong X, Ding H, et al.

    International journal of nursing studies 2025; (163()):104997 doi:10.1016/j.ijnurstu.2025.104997.

    PMID: 39961652
  17. 17

    The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.

    Di Lisi D, Madaudo C, Faro DC, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2024; (25(3)):218-224 doi:10.2459/JCM.0000000000001589.

    PMID: 38305134

This page is for informational purposes only and does not constitute medical advice. Your oncology and cardiology teams should interpret your heart-test results and guide decisions about chemotherapy and heart-protective treatment.

Get notified when new evidence is published on Cardiomyopathy due to anthracyclines.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.